Regeneron Pharmaceuticals REGN Libtayo — Revenue
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Regeneron Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: Regeneron Pharmaceuticals’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →
Ask your AI about Regeneron Pharmaceuticals's libtayo — revenue.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Regeneron Pharmaceuticals's libtayo — revenue?
- Regeneron Pharmaceuticals (REGN) reported libtayo — revenue of $438.2M in Q1 2026.
- How has Regeneron Pharmaceuticals's libtayo — revenue changed year-over-year?
- Regeneron Pharmaceuticals's libtayo — revenue increased by 53.7% year-over-year, from $285.1M to $438.2M.
- What is the long-term trend for Regeneron Pharmaceuticals's libtayo — revenue?
- Over 3 years (2022 to 2025), Regeneron Pharmaceuticals's libtayo — revenue has grown at a 48.1% compound annual growth rate (CAGR), from $447.5M to $1.45B.
- What does libtayo — revenue mean?
- This metric represents the total net product sales generated from the commercialization of Libtayo, an anti-PD-1 monoclonal antibody therapy used in oncology. It reflects the market adoption and therapeutic demand for this specific drug within the company's broader portfolio of cancer treatments. Revenue is recognized after accounting for rebates, discounts, and other sales-related adjustments.